A major limitation of menin inhibitor monotherapy is acquired resistance. Up to 39% of patients on revumenib develop mutations in the menin (MEN1) gene. These mutations prevent the drug from binding to its target, leading to rapid relapse and highlighting the need for combination therapies or next-generation agents.

Subgroup analyses of menin inhibitor trials reveal a key difference for treatment sequencing. Patients with prior venetoclax exposure showed lower response rates to Revumenitib. In contrast, early data for Ziftomenib suggests prior venetoclax use did not negatively impact its efficacy.

The same cancer-driving mutation behaves differently depending on the cell's internal "wiring." For example, a drug targeting a mutation works in melanoma but induces resistance in colorectal cancer due to a bypass pathway. This cellular context is why genetic data alone is insufficient.

When an AML patient presents with multiple targetable mutations (FLT3, NPM1, IDH), clinicians follow a treatment hierarchy. FLT3-targeted therapy is typically the first choice due to its aggressive phenotype. Menin inhibitors for NPM1 are next, followed by IDH inhibitors, guiding treatment decisions in complex cases.

Preclinical data and early clinical findings suggest menin inhibitors could be effective against rare NUP98-rearranged leukemias. This is based on similarities in downstream pathways to the approved KMT2A and NPM1 mutations, hinting at a broader mechanism of action for this drug class.

Many blood cancers are better understood as "regulatory problems" driven by epigenetic failures—the systems controlling which genes are turned on or off. This shifts the therapeutic focus from targeting DNA mutations to developing drugs, like IDH inhibitors, that correct these underlying control mechanisms.

Unlike typical targeted therapies that block a mutated receptor, menin inhibitors work by disrupting a master transcription complex. This forces leukemic cells to mature (differentiate) into terminal forms like neutrophils, after which they naturally die off.

A high-sensitivity NGS assay for cell-free DNA (cfDNA) can detect emerging resistance mutations in the MEN1 gene. This allows for early identification of treatment failure, potentially months before a patient shows clinical signs of relapse, opening a window for proactive therapeutic adjustments like switching inhibitors.

Up to a third of CDK inhibitor resistance cases show no known DNA mutations. Dr. Wander suggests epigenetic factors, like DNA methylation altering chromatin architecture, are responsible. These "dark matter" events turn genes on or off without changing the DNA code, requiring new blood-based profiling technologies to detect and understand resistance.